A little more than a year into the US launch of Brexafemme (ibrexafungerp), a novel triterpenoid antifungal for treating vulvovaginal candidiasis (VVC), Scynexis, Inc. announced a strategic shift on 20 October, under which it will wind down its commercial efforts for the product, downsize its workforce and retrain its focus for the drug to hospital-based indications.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?